AT15 Antibody

How do I properly validate antibody specificity for my research experiments?

Antibody validation is critical for ensuring reliable experimental results. A comprehensive validation approach should include:

• Western blot analysis: Confirm the presence of bands at the expected molecular weight. For example, in search result , the anti-ATG12 antibody (ab155589) demonstrated specificity by detecting bands at the predicted sizes in various cell lysates, including a 52 kDa band representing the ATG12-ATG5 complex.

• Knockout validation: Compare antibody reactivity between wild-type and knockout samples. As shown in search result , the Anti-ATG12 antibody was validated using ATG12 knockout THP-1 cell lysate, demonstrating no signal at the expected size in the knockout cells.

• Multiple detection methods: Cross-validate using different techniques such as WB, IHC-P, and ICC/IF.

• Positive and negative controls: Include appropriate controls in each experiment. For instance, search result indicates HeLa cells, HL-60 cells, Human cerebellum, and other samples as positive controls for ACADM/MCAD antibody testing.

What are the optimal storage conditions for maintaining antibody functionality long-term?

To maintain antibody functionality:

• Temperature: Most antibodies should be stored at +4°C for short-term storage, as indicated in search result for the Anti-ACADM/MCAD antibody.

• Avoid freeze-thaw cycles: Search result specifically notes "Do Not Freeze" for some antibodies, as repeated freeze-thaw cycles can lead to decreased activity.

• Buffer conditions: Typical storage buffers maintain pH around 7.5 with preservatives like 0.02% sodium azide, as mentioned in search result .

• Aliquoting: Divide antibodies into small aliquots to minimize exposure to room temperature and repeated freeze-thaw cycles.

• Follow manufacturer guidelines: Always adhere to specific storage recommendations provided by the manufacturer, as conditions may vary between antibody types.

How should I design a binding assay protocol to accurately measure antibody-antigen interactions?

Based on search result , a systematic approach to binding assay design includes:

Step-by-step protocol:

• Add test compound dilutions (5 μL of 3X concentration)

• Add kinase/antibody mixture (5 μL of 3X concentration)

• Add tracer (5 μL of 3X concentration)

• Mix, cover, and read plate after 1 hour incubation

Typical final assay conditions:

For data analysis:

• Calculate TR-FRET emission ratio by dividing the acceptor/tracer emission (665 nm) by the antibody/donor emission (615 nm)

• Plot the TR-FRET ratio against the log of test compound concentration

• Fit to a sigmoidal dose-response curve with variable slope to calculate the EC50 concentration

How can I optimize immunohistochemistry protocols for detecting low-abundance antigens?

For detecting low-abundance antigens:

• Epitope retrieval optimization: As noted in search result , heat-mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 20 minutes significantly improves detection sensitivity.

• Signal amplification: Employ polymer-based detection systems like the Bond Polymer Refine Detection kit mentioned in to enhance signal without increasing background.

• Antibody concentration titration: Perform serial dilutions to determine optimal concentration. For example, search result indicates using Anti-ATG12 antibody at 1/500 dilution for IHC-P applications.

• Extended incubation times: Consider longer primary antibody incubation times (overnight at 4°C) as mentioned in search result for CD155 detection in HeLa cells.

• Negative controls: Always include secondary-only controls to assess background, as shown in search result where "Image inset shows absence of staining in secondary antibody only control."

How do post-translational modifications affect antibody recognition and what methods can detect these modifications?

Post-translational modifications (PTMs) significantly impact antibody recognition through:

• Epitope masking: PTMs can alter the three-dimensional structure of proteins, potentially hiding antibody binding sites.

• Creation of neo-epitopes: Some antibodies specifically recognize modified forms of proteins, as seen in phospho-specific antibodies.

Detection methods for PTMs in antibody research:

• Mass spectrometry: Gold standard for identifying and mapping PTMs on antibodies

• Western blotting with modification-specific antibodies: For detecting phosphorylation, glycosylation, etc.

• 2D gel electrophoresis: To separate protein isoforms with different modifications

• Enzymatic treatments: Using phosphatases or glycosidases before antibody detection to confirm specificity

What approaches can resolve conflicting antibody data between different experimental platforms?

When facing conflicting antibody results:

• Cross-platform validation: As demonstrated in search result , validate findings using multiple techniques (WB, IHC-P, ICC/IF) to build a consistent picture.

• Epitope mapping: Determine if different antibodies recognize distinct epitopes that might be differentially accessible in various applications.

• Sample preparation effects: Consider how different fixation or extraction methods might affect epitope availability. Search result notes specific fixation conditions: "Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes."

• Quantitative analysis: Use quantitative methods across platforms to determine if differences are qualitative or quantitative.

• Knockout/knockdown controls: Include genetic controls to definitively establish specificity, as shown in search result with the use of knockout cell lines.

What is the evidence supporting approval of therapeutic antibodies based on biomarker changes versus clinical outcomes?

This question addresses an important regulatory debate highlighted in search result :

Researchers are advocating for a paradigm shift in regulatory approval processes for anti-amyloid antibodies in Alzheimer's disease. Key points include:

• Traditional approach: FDA currently requires cognitive/clinical change to prove efficacy

• Proposed biomarker approach: Granting approval based on significant amyloid clearance (below 15-20 centiloid) plus reasonable safety data

Supporting evidence:

• Four decades of research establishing amyloid aggregation as causal in Alzheimer's disease

• Downstream biomarkers reflect disease pathobiology and indicate interference with central disease pathway

• Similarity to atherosclerosis treatment paradigm with statins

Counterarguments:

• Lack of comprehensive data sharing to validate plaque reduction as a surrogate marker

• Need for longer-term safety data (at least one year)

• Requirement for specific demonstration of amyloid lowering in individuals with mild dementia

As noted by one researcher: "Belief and guesses are not adequate validators of efficacy. If we are going to advance biomarkers such as plaques as surrogate clinical outcomes in Alzheimer's, then we must be willing to open science and share data to validate what are claimed to be meaningful outcomes."

How does antibody persistence vary across therapeutic applications and what factors influence long-term immunity?

Understanding antibody persistence is crucial for vaccine development and therapeutic antibody applications:

Long-term persistence data:

• A 15-year follow-up study of hepatitis A vaccination (search result ) found that 97.3-100% of subjects remained seropositive after two doses, with geometric mean concentrations of 289.2-367.4 mIU/ml at year 15.

Factors influencing persistence:

• Vaccination schedule: No significant difference in long-term antibody persistence was observed between 0,6 month and 0,12 month vaccination schedules .

• Immune memory: Even subjects who became seronegative mounted immune responses to challenge doses, demonstrating persistent immune memory.

• Timing of assessment: The dynamic nature of antibody responses includes rapid early increases followed by gradual declines, as shown in search result where antibody levels peaked at 15-30 days post-symptom onset.

Application to COVID-19:

• Search result showed that different antibody isotypes (IgG, IgM, IgA) and targets (S1-RBD, S2-ECD, N) exhibit distinct persistence patterns, with S2-IgG maintaining a 85.7% seropositive rate from 213-416 days after symptom onset.

What methodologies are available for assessing antibody thermostability and how does it correlate with affinity?

Methods for assessing antibody thermostability:

• Differential Scanning Fluorimetry (DSF): Measures melting temperature (Tm) to assess thermal stability.

• Differential Scanning Calorimetry (DSC): Provides thermodynamic parameters of unfolding.

• Size Exclusion Chromatography (SEC): Detects aggregation after thermal stress.

From search result , thermostability assessment showed:

• Optimized S309 antibody variants had a Tm of 72.8°C compared to 72.5°C for wild-type

• Introduction of VH N55Q substitution in sotrovimab decreased Tm to 69.6°C

• Affinity-matured variants of mAb114 UCA demonstrated increased Tm from 74.5°C to 82.5°C

How can I assess and minimize immunogenicity risks when developing therapeutic antibodies?

Assessment methods for immunogenicity:

• Antidrug-antibody (ADA) testing: Search result reports "The incidences of positive antidrug-antibody (ADA) were 1/3, 1/6, 1/8, and 1/8" across different dose cohorts.

• Neutralizing antibody (Nab) responses: "3 of 25 (3/25) participants had positive Nab responses" , indicating potential neutralization of the therapeutic effect.

• In silico prediction: Computational tools can predict peptide binding to HLA class I and II molecules, as noted in search result : "our affinity-matured variants have no significant increase in the number of computationally predicted peptide binders to both human leukocyte antigen (HLA) class I and class II."

Strategies to minimize immunogenicity:

• Humanization: Using fully human antibodies reduces foreign sequences that could trigger immune responses.

• Removal of T-cell epitopes: Eliminating sequences recognized by T-cells while maintaining functionality.

• Monitoring for temporal patterns: As seen in search result , all participants with positive ADA and Nab responses "became negative for ADA and Nab responses at subsequent time points," suggesting transient responses.

How are protein language models being applied to optimize antibody affinity and specificity?

Research in search result demonstrates innovative applications of protein language models for antibody optimization:

Methodology:

• Using general protein language models to "efficiently evolve human antibodies by suggesting mutations that are evolutionarily plausible"

• The approach focuses on identifying mutations with highest likelihood of improving binding while maintaining structural integrity

Key findings:

• For mAb114 UCA, language model-guided evolution achieved a 160-fold improvement in binding affinity to ebolavirus GP

• For C143 antibody, the approach achieved a 13-fold improvement for Beta S-6P and 3.8-fold improvement for Omicron RBD

• The models successfully explored "alternative evolutionary routes" beyond naturally occurring mutations

Additional benefits:

• 21 out of 31 language-model-recommended variants had higher melting temperatures than wild-type

• No substantial changes in polyspecificity were observed, keeping values "within a therapeutically viable range"

• No significant increase in predicted immunogenicity was detected

This approach represents a significant advancement over traditional directed evolution methods by leveraging computational modeling to predict beneficial mutations.

What are the current approaches for developing cross-species reactive antibodies for immunotherapy research?

Search result highlights methodologies for developing cross-species reactive antibodies:

Development strategy:

• Using phage display human antibody libraries to screen for antibodies that bind to both human and mouse TIGIT

• Two-round selection process: "We used hTIGIT in the first round of panning and hTIGIT or mTIGIT in the second round of panning as Ags"

Characterization methods:

• ELISA-based binding and competition assays

• Flow cytometry analyses with CHO cell lines expressing target proteins

• Functional assays measuring blockade of receptor-ligand interactions

• Cytotoxicity assays measuring effector functions

Benefits of cross-species reactive antibodies:

• Enable preclinical testing in animal models with the same antibody used for human applications

• Allow better translation of research findings from animal models to clinical studies

• Provide deeper insights into conserved epitopes and binding mechanisms